# Forensic Dossier: Study Forensics: Novel cholesterol drug dramatically lowers LDL but cardiovascular outcomes unknown

**Run ID:** `mc2_study-forensics-032_claude_opus_bf867c`  
**Task:** study-forensics-032 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-06T16:25:50.665181+00:00  
**Task Family:** mechanism_vs_evidence  
**Trap Type:** biomarker_sold_as_clinical_benefit  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Opus
**Winner:** Claude Opus — **40.0/100** (margin: 0.0)
**Failure modes:** confidence_mismatch, decorative_uncertainty, wrong_answer
**Forensic flags:** 3
**Consistency findings:** 6
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Opus | 0.0/30 | 0.7/8 | 4.8/8 | 4.8/6 | 2.7/6 | 6.0/6 | 4.0/8 | 8.0/8 | 0.0/10 | 10.0/10 | **40.0/100** |

## Study Forensics Audit

### Claude Opus

**Classification:** `overclaim` [x] (gold: `mechanism_vs_evidence`)
**Finding Recall:** 100%
**Matched Findings:** mechanism_not_demonstrated, conclusion_exceeds_results
**Extra Findings:** unsupported_generalization, correlation_as_causation

## Reasoning Integrity Audit

### Claude Opus
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 5

## Mechanism Analysis

### Claude Opus
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Opus
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "overclaim"


## Forensic Flags

### Claude Opus

- **[MINOR]** `calibration_gap`: Confidence 0.95 is very high despite listing 3 uncertainties — possible performative calibration
  - `confidence`: "confidence: 0.95"
  - `uncertainties[0]`: "Whether LDL reduction of this magnitude typically translates to clinical benefit"
- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "overclaim"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "overclaim"


## Evidence Map

### Claude Opus

**Correctness:** 0.0/30
  - (+) `final_answer`: "overclaim"
    _Agent's answer for correctness check_
  - Note: No match (got: overclaim)

**Support Strength:** 1.2/8
  - (+) `final_answer`: "overclaim"
    _Conclusion grounded by reasoning chain_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 5
  - Note: Reasoning graph confirms conclusion grounding

**Structural Reasoning:** 4.8/8
  - (+) `steps[2]`: "Analyzed the company's claims: 'major breakthrough in cardiovascular protection' and 'transform outcomes for patients at"
    _Most informative reasoning step_
  - Note: 5 reasoning steps
  - Note: Low step utility: 0/5 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[3]`: "The company is making public statements about the drug's impact on cardiovascular events"
    _Most substantive assumption_
  - Note: 4/4 substantive assumptions

**Uncertainty Handling:** 2.7/6
  - (+) `uncertainties[0]`: "Whether LDL reduction of this magnitude typically translates to clinical benefit"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.95"
    _Stated confidence level_
  - (-) `uncertainties[1]`: "The exact wording used by executives vs. paraphrasing in the text"
    _Listed but never addressed in reasoning_
  - Note: 3 uncertainties (3 substantive)
  - Note: 1 decorative uncertainty(ies)

**Alternative Hypothesis Quality:** 6.0/6
  - (+) `alternative_hypotheses[0]`: "mechanism_vs_evidence - but the mechanism (LDL reduction) was actually tested in humans, not just described"
    _Most substantive alternative hypothesis_
  - Note: 3 alternative hypotheses considered
  - Note: 3/3 include rejection reasoning

**Self Monitoring Quality:** 4.0/8
  - (+) `self_check[2]`: "Is this a common practice that might be acceptable? Even if common, it's still epistemically problematic to claim clinic"
    _Most substantive self-verification step_
  - Note: 3 self-check items
  - Note: Self-check quality: 0 deep, 3 arithmetic, 0 fluff

**Mechanism Quality:** 0.0/10
  - Note: Neither names concept nor explains mechanism

**Communication Efficiency:** 10.0/10
  - Note: Signal density: 0.72, 302 words

**Insight Depth:** 8.0/8
  - (+) `(output text)`: "overclaim: extrapolating from surrogate endpoints to clinical outcomes without"
    _Insight 'surrogate endpoint' matched (exact)_
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Opus

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'mechanism_vs_evidence'
  - `final_answer`: "overclaim"
  - _Impacts: correctness_

**MAJOR:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Study classification incorrect: expected 'mechanism_vs_evidence', detected 'overclaim'
  - `final_answer`: "overclaim"
  - _Impacts: correctness_

**MINOR:**
- **Confidence Mismatch** `[MEDIUM CONFIDENCE]`: Very high confidence (0.95) on medium task
  - `confidence`: "confidence: 0.95"
  - _Impacts: uncertainty_handling_

**STYLISTIC:**
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'The exact wording used by executives vs. paraphrasing in the...' is listed but not addressed
  - `uncertainties[1]`: "The exact wording used by executives vs. paraphrasing in the text"
  - _Impacts: uncertainty_handling_


## Consistency & Grounding Audit

### Claude Opus

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/12 content words)
  - `key_claims[0]`: "Company claims the drug provides 'cardiovascular protection' and will 'transform outcomes' for heart"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/8 content words)
  - `key_claims[1]`: "These clinical outcome claims are based solely on 12-week biomarker data"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/8 content words)
  - `key_claims[2]`: "No cardiovascular events were tracked and outcomes data won't be available for 4+ years"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/10 content words)
  - `key_claims[3]`: "This is textbook overclaim: extrapolating from surrogate endpoints to clinical outcomes without evid"
- **[WARN]** `[MEDIUM CONFIDENCE]` `confidence_uncertainty`: Confidence 0.95 is very high despite listing 3 uncertainties — possible performative calibration
  - `confidence`: "confidence: 0.95"
- **[WARN]** `[HEURISTIC]` `decorative_uncertainty`: Uncertainty 2 appears decorative — not addressed in reasoning or self-check
  - `uncertainties[1]`: "The exact wording used by executives vs. paraphrasing in the text"


## Agent Profiles

### Claude Opus (claude-opus-4-20250514)
**Parse OK:** True | **Latency:** 17788ms

**Final Answer:** overclaim

**Confidence:** 0.95

**Assumptions:**
- The text accurately represents what the company announced
- Phase 2 trials typically focus on efficacy and safety rather than clinical outcomes
- LDL reduction is an established biomarker but not equivalent to clinical outcomes
- The company is making public statements about the drug's impact on cardiovascular events

**Reasoning Steps:**
1. Identified the actual measured outcome: 65% LDL reduction over 12 weeks
2. Noted what was NOT measured: cardiovascular events, heart attacks, strokes
3. Analyzed the company's claims: 'major breakthrough in cardiovascular protection' and 'transform outcomes for patients at high risk of heart attack and stroke'
4. Recognized the gap: company claims about cardiovascular protection and clinical outcomes based only on biomarker data
5. Confirmed this is overclaim: conclusions about heart attacks and strokes exceed the evidence of LDL reduction alone

**Key Claims:**
- Company claims the drug provides 'cardiovascular protection' and will 'transform outcomes' for heart attack and stroke
- These clinical outcome claims are based solely on 12-week biomarker data
- No cardiovascular events were tracked and outcomes data won't be available for 4+ years
- This is textbook overclaim: extrapolating from surrogate endpoints to clinical outcomes without evidence

**Alternative Hypotheses:**
- mechanism_vs_evidence - but the mechanism (LDL reduction) was actually tested in humans, not just described
- solid - but the claims clearly exceed the data
- correlation_vs_causation - but this is an intervention study, not observational

**Uncertainties:**
- Whether LDL reduction of this magnitude typically translates to clinical benefit
- The exact wording used by executives vs. paraphrasing in the text
- Whether the company has unpublished data supporting their claims

**Self-Verification:**
- Did I correctly identify what was measured vs. claimed? Yes - LDL reduction vs. cardiovascular outcomes
- Am I being too harsh? No - the company explicitly claimed impact on heart attacks and strokes without measuring them
- Is this a common practice that might be acceptable? Even if common, it's still epistemically problematic to claim clinical outcomes from biomarker data alone

**Dimension Scores:**
- Correctness: 0.0/30 `..........`
- Support Strength: 0.7/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 2.7/6 `####......`
- Alternative Hypothesis Quality: 6.0/6 `##########`
- Self Monitoring Quality: 4.0/8 `#####.....`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 0.0/10 `..........`
- Communication Efficiency: 10.0/10 `##########`


## Final Verdict

**Solo run: Claude Opus** scored **40.0/100**.

**Best per dimension:**
- Correctness: Claude Opus (0.0/30)
- Support Strength: Claude Opus (0.7/8)
- Structural Reasoning: Claude Opus (4.8/8)
- Assumption Discipline: Claude Opus (4.8/6)
- Uncertainty Handling: Claude Opus (2.7/6)
- Alternative Hypothesis Quality: Claude Opus (6.0/6)
- Self Monitoring Quality: Claude Opus (4.0/8)
- Insight Depth: Claude Opus (8.0/8)
- Mechanism Quality: Claude Opus (0.0/10)
- Communication Efficiency: Claude Opus (10.0/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Opus | 17.8s | 40.0/100 | 2.2 |

Failure modes observed: confidence_mismatch, decorative_uncertainty, wrong_answer.
